Gallium 68 PSMA-11 PET/MR Imaging in Patients with Intermediate- or High-Risk Prostate Cancer

References

• 1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017;67(1):7–30.
  Medline Google Scholar
• 2. Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United States, 2009: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin 2009;59(1):27–41.
  Medline Google Scholar
• 3. Lacy GL 2nd, Soderdahl DW, Hernandez J. Optimal cost-effective staging evaluations in prostate cancer. Curr Urol Rep 2007;8(3):190–196.
  Medline Google Scholar
• 4. Roscigno M, Sangalli M, Mazzoccoli B, Scattoni V, Da Pozzo L, Rigatti P. Medical therapy of prostate cancer. A review. Minerva Urol Nefrol 2005;57(2):71–84.
  Medline Google Scholar
• 5. Oh WK, Kantoff PW. Treatment of locally advanced prostate cancer: is chemotherapy the next step? J Clin Oncol 1999;17(11):3664–3675.
  Medline Google Scholar
• 6. Jani AB. Management strategies for locally advanced prostate cancer. Drugs Aging 2006;23(2):119–129.
  Medline Google Scholar
• 7. Puech P, Rouvière O, Renard-Penna R, et al. Prostate cancer diagnosis: multiparametric MR-targeted biopsy with cognitive and transrectal US-MR fusion guidance versus systematic biopsy––prospective multicenter study. Radiology 2013;268(2):461–469.
  Google Scholar
• 8. NCCN Clinical Practice Guidelines in Oncology. Prostate Cancer Version 2.2017. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Published February 21, 2017. Accessed April 7, 2017.
  Google Scholar
• 9. Khan MA, Partin AW. Management of high-risk populations with locally advanced prostate cancer. Oncologist 2003;8(3):259–269.
  Medline Google Scholar
• 10. Sweat SD, Pacelli A, Murphy GP, Bostwick DG. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology 1998;52(4):637–640.
  Medline Google Scholar
• 11. Eder M, Eisenhut M, Babich J, Haberkorn U. PSMA as a target for radiolabelled small molecules. Eur J Nucl Med Mol Imaging 2013;40(6):819–823.
  Medline Google Scholar
• 12. Hillier SM, Maresca KP, Femia FJ, et al. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res 2009;69(17):6932–6940.
  Medline Google Scholar
• 13. Afshar-Oromieh A, Malcher A, Eder M, et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging 2013;40(4):486–495.
  Medline Google Scholar
• 14. Antoch G, Bockisch A. Combined PET/MRI: a new dimension in whole-body oncology imaging? Eur J Nucl Med Mol Imaging 2009;36(Suppl 1):S113–S120.
  Medline Google Scholar
• 15. Engeler CE, Wasserman NF, Zhang G. Preoperative assessment of prostatic carcinoma by computerized tomography: weaknesses and new perspectives. Urology 1992;40(4):346–350.
  Medline Google Scholar
• 16. Eder M, Neels O, Müller M, et al. Novel preclinical and radiopharmaceutical aspects of [68Ga]Ga-PSMA-HBED-CC: a new PET tracer for imaging of prostate cancer. Pharmaceuticals (Basel) 2014;7(7):779–796.
  Medline Google Scholar
• 17. Iagaru A, Mittra E, Minamimoto R, et al. Simultaneous whole-body time-of-flight 18F-FDG PET/MRI: a pilot study comparing SUVmax with PET/CT and assessment of MR image quality. Clin Nucl Med 2015;40(1):1–8.
  Medline Google Scholar
• 18. Loening AM, Saranathan M, Ruangwattanapaisarn N, Litwiller DV, Shimakawa A, Vasanawala SS. Increased speed and image quality in single-shot fast spin echo imaging via variable refocusing flip angles. J Magn Reson Imaging 2015;42(6):1747–1758.
  Medline Google Scholar
• 19. Fung MM, Estkowski L, Xu D, et al. Coronal whole body diffusion imaging with 2D spatially selective excitation (FOCUS) [abstr]. In: Proceedings of the Twenty-Second Meeting of the International Society for Magnetic Resonance in Medicine. Berkeley, Calif: International Society for Magnetic Resonance in Medicine, 2014.
  Google Scholar
• 20. Rauscher I, Maurer T, Fendler WP, Sommer WH, Schwaiger M, Eiber M. (68)Ga-PSMA ligand PET/CT in patients with prostate cancer: how we review and report. Cancer Imaging 2016;16(1):14.
  Medline Google Scholar
• 21. Weinreb JC, Barentsz JO, Choyke PL, et al. PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2. Eur Urol 2016;69(1):16–40.
  Medline Google Scholar
• 22. D’Amico AV, Whittington R, Malkowicz SB, et al. A multivariable analysis of clinical factors predicting for pathological features associated with local failure after radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys 1994;30(2):293–302.
  Medline Google Scholar
• 23. Afshar-Oromieh A, Avtzi E, Giesel FL, et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2015;42(2):197–209.
  Medline Google Scholar
• 24. Eiber M, Maurer T, Souvatzoglou M, et al. Evaluation of hybrid ⁶⁸Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med 2015;56(5):668–674.
  Medline Google Scholar
• 25. Rauscher I, Maurer T, Beer AJ, et al. Value of 68Ga-PSMA HBED-CC PET for the assessment of lymph node metastases in prostate cancer patients with biochemical recurrence: comparison with histopathology after salvage lymphadenectomy. J Nucl Med 2016;57(11):1713–1719.
  Medline Google Scholar
• 26. Schmuck S, Mamach M, Wilke F, et al. Multiple Time-Point 68Ga-PSMA I&T PET/CT for Characterization of Primary Prostate Cancer: Value of Early Dynamic and Delayed Imaging. Clin Nucl Med 2017;42(6):e286–e293.
  Medline Google Scholar
• 27. Fendler WP, Schmidt DF, Wenter V, et al. 68Ga-PSMA PET/CT Detects the Location and Extent of Primary Prostate Cancer. J Nucl Med 2016;57(11):1720–1725.
  Medline Google Scholar
• 28. Giesel FL, Sterzing F, Schlemmer HP, et al. Intra-individual comparison of (68)Ga-PSMA-11-PET/CT and multi-parametric MR for imaging of primary prostate cancer. Eur J Nucl Med Mol Imaging 2016;43(8):1400–1406.
  Medline Google Scholar
• 29. Eiber M, Weirich G, Holzapfel K, et al. Simultaneous⁶⁸Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer. Eur Urol 2016;70(5):829–836.
  Medline Google Scholar
• 30. Sachpekidis C, Kopka K, Eder M, et al. 68Ga-PSMA-11 Dynamic PET/CT Imaging in Primary Prostate Cancer. Clin Nucl Med 2016;41(11):e473–e479.
  Medline Google Scholar
• 31. Moldovan PC, Van den Broeck T, Sylvester R, et al. What is the negative predictive value of multiparametric magnetic resonance imaging in excluding prostate cancer at biopsy? a systematic review and meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel. Eur Urol 2017;72(2):250–266.
  Medline Google Scholar
• 32. Pepe P, Garufi A, Priolo G, Pennisi M. Can 3-Tesla pelvic phased-array multiparametric MRI avoid unnecessary repeat prostate biopsy in patients with PSA < 10 ng/mL? Clin Genitourin Cancer 2015;13(1):e27–e30.
  Medline Google Scholar
• 33. Vinet M, Vlaeminck-Guillem V, Rouvière O, et al. Does PCA3 score and prostatic MRI help selection of patients scheduled for initial prostatic biopsy? [in French]. Prog Urol 2013;23(2):121–127.
  Medline Google Scholar
• 34. Radtke JP, Kuru TH, Boxler S, et al. Comparative analysis of transperineal template saturation prostate biopsy versus magnetic resonance imaging targeted biopsy with magnetic resonance imaging-ultrasound fusion guidance. J Urol 2015;193(1):87–94.
  Medline Google Scholar
• 35. Öbek C, Doğanca T, Demirci E, et al. The accuracy of⁶⁸Ga-PSMA PET/CT in primary lymph node staging in high-risk prostate cancer. Eur J Nucl Med Mol Imaging 2017;44(11):1806–1812.
  Medline Google Scholar
• 36. Hijazi S, Meller B, Leitsmann C, et al. Pelvic lymph node dissection for nodal oligometastatic prostate cancer detected by 68Ga-PSMA-positron emission tomography/computerized tomography. Prostate 2015;75(16):1934–1940.
  Medline Google Scholar
• 37. Herlemann A, Wenter V, Kretschmer A, et al. (68)Ga-PSMA positron emission tomography/computed tomography provides accurate staging of lymph node regions prior to lymph node dissection in patients with prostate cancer. Eur Urol 2016;70(4):553–557.
  Medline Google Scholar
• 38. Maurer T, Gschwend JE, Rauscher I, et al. Diagnostic efficacy of (68)gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer. J Urol 2016;195(5):1436–1443.
  Medline Google Scholar
• 39. Pinaquy JB, De Clermont-Galleran H, Pasticier G, et al. Comparative effectiveness of [(18) F]-fluorocholine PET-CT and pelvic MRI with diffusion-weighted imaging for staging in patients with high-risk prostate cancer. Prostate 2015;75(3):323–331.
  Medline Google Scholar
• 40. Uprimny C, Kroiss AS, Decristoforo C, et al. (68)Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour. Eur J Nucl Med Mol Imaging 2017;44(6):941–949.
  Medline Google Scholar
• 41. Woythal N, Arsenic R, Kempkensteffen C, et al. Immunohistochemical validation of PSMA expression measured by 68Ga-PSMA PET/CT in primary prostate cancer. J Nucl Med 2018;59(2):238–243.
  Medline Google Scholar
• 42. Uhlman MA, Sun L, Stackhouse DA, et al. Tumor volume, tumor percentage involvement, or prostate volume: which is predictive of prostate-specific antigen recurrence? Urology 2010;75(2):460–466.
  Medline Google Scholar
• 43. Afshar-Oromieh A, Sattler LP, Mier W, et al. The clinical impact of additional late PET/CT imaging with⁶⁸Ga-PSMA-11 (HBED-CC) in the diagnosis of prostate cancer. J Nucl Med 2017;58(5):750–755.
  Medline Google Scholar
• 44. Schmuck S, Nordlohne S, von Klot CA, et al. Comparison of standard and delayed imaging to improve the detection rate of [⁶⁸Ga]PSMA I&T PET/CT in patients with biochemical recurrence or prostate-specific antigen persistence after primary therapy for prostate cancer. Eur J Nucl Med Mol Imaging 2017;44(6):960–968.
  Medline Google Scholar
• 45. Rahbar K, Ahmadzadehfar H, Kratochwil C, et al. German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med 2017;58(1):85–90.
  Medline Google Scholar
• 46. Zechmann CM, Afshar-Oromieh A, Armor T, et al. Radiation dosimetry and first therapy results with a (124)I/ (131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging 2014;41(7):1280–1292.
  Medline Google Scholar
• 47. Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer 1998;82(11):2256–2261.
  Medline Google Scholar